Equillium (NASDAQ:EQ) & Curative Biotechnology (OTCMKTS:CUBT) Head-To-Head Contrast

Curative Biotechnology (OTCMKTS:CUBT) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Curative Biotechnology and Equillium, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curative Biotechnology	0	0	0	0	0.00
Equillium	1	2	2	0	2.20

Equillium has a consensus price target of $6.00, suggesting a potential upside of 142.91%. Given Equillium’s stronger consensus rating and higher possible upside, analysts clearly believe Equillium is more favorable than Curative Biotechnology.

Profitability

This table compares Curative Biotechnology and Equillium’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Curative Biotechnology	N/A	N/A	N/A
Equillium	N/A	-148.79%	-109.44%

Volatility and Risk

Curative Biotechnology has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500. Comparatively, Equillium has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500.

Earnings & Valuation

This table compares Curative Biotechnology and Equillium”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curative Biotechnology	N/A	N/A	N/A	N/A	N/A
Equillium	$41.10 million	3.66	-$8.07 million	($0.62)	-3.98

Curative Biotechnology has higher earnings, but lower revenue than Equillium.

Insider and Institutional Ownership

27.1% of Equillium shares are owned by institutional investors. 30.3% of Equillium shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Equillium beats Curative Biotechnology on 7 of the 9 factors compared between the two stocks.

About Curative Biotechnology

Curative Biotechnology, Inc., a development-stage biomedical company, focuses on novel treatments for rare diseases. The company focuses on therapies with potentially accelerated development paths as a result of the disease, the nature of the therapeutic itself, or the stage of clinical development. Its pipeline candidates include CURB906, an antibody-drug conjugate for targeting CD56 positive brain tumors; and IMT504, a novel immune therapy to treat rabies. The company has an agreement with Mid-Atlantic BioTherapeutics, Inc. to develop the COVID-19 vaccine. Curative Biotechnology, Inc. was founded in 1995 and is based in Boca Raton, Florida.

About Equillium

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.